Detailed information for compound 18306

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 473.972 | Formula: C23H24ClN3O4S
  • H donors: 2 H acceptors: 4 LogP: 2.92 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 1
  • SMILES: OCCc1ccc(cc1)NC(=O)C1CCN(CC1)C(=O)Cn1c(=O)sc2c1cc(Cl)cc2
  • InChi: 1S/C23H24ClN3O4S/c24-17-3-6-20-19(13-17)27(23(31)32-20)14-21(29)26-10-7-16(8-11-26)22(30)25-18-4-1-15(2-5-18)9-12-28/h1-6,13,16,28H,7-12,14H2,(H,25,30)
  • InChiKey: XAAGNWBZWQMGMG-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens neuropeptide Y receptor Y5 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trichomonas vaginalis geranylgeranyl pyrophosphate synthase, putative 0.0753 1 0.5
Echinococcus multilocularis farnesyl pyrophosphate synthase 0.0753 1 1
Mycobacterium ulcerans geranylgeranyl pyrophosphate synthase 0.0753 1 1
Treponema pallidum octaprenyl-diphosphate synthase 0.019 0 0.5
Wolbachia endosymbiont of Brugia malayi geranylgeranyl pyrophosphate synthase 0.019 0 0.5
Schistosoma mansoni farnesyl pyrophosphate synthase 0.0753 1 1
Wolbachia endosymbiont of Brugia malayi geranylgeranyl pyrophosphate synthase 0.019 0 0.5
Trypanosoma cruzi farnesyl pyrophosphate synthase 0.0753 1 1
Mycobacterium tuberculosis Probable geranylgeranyl pyrophosphate synthetase IdsA2 (ggppsase) (GGPP synthetase) (geranylgeranyl diphosphate synthase) 0.0753 1 1
Toxoplasma gondii polyprenyl synthetase superfamily protein 0.0753 1 1
Entamoeba histolytica geranylgeranyl pyrophosphate synthase, putative 0.019 0 0.5
Leishmania major farnesyl pyrophosphate synthase 0.0753 1 1
Plasmodium vivax geranylgeranyl pyrophosphate synthase 0.0753 1 1
Trichomonas vaginalis geranylgeranyl pyrophosphate synthase, putative 0.0753 1 0.5
Loa Loa (eye worm) polyprenyl synthetase 0.0753 1 1
Mycobacterium ulcerans geranylgeranyl pyrophosphate synthase 0.0753 1 1
Chlamydia trachomatis geranylgeranyl pyrophosphate synthase 0.019 0 0.5
Trypanosoma cruzi farnesyl pyrophosphate synthase, putative 0.0753 1 1
Entamoeba histolytica geranylgeranyl pyrophosphate synthetase, putative 0.019 0 0.5
Trichomonas vaginalis geranylgeranyl diphosphate synthase, putative 0.0753 1 0.5
Plasmodium falciparum geranylgeranyl pyrophosphate synthase, putative 0.0753 1 1
Giardia lamblia Farnesyl diphosphate synthase 0.0753 1 0.5
Echinococcus granulosus farnesyl pyrophosphate synthase 0.0753 1 1
Trypanosoma brucei farnesyl pyrophosphate synthase 0.0753 1 1
Entamoeba histolytica bifunctional short chain isoprenyl diphosphate synthase, putative 0.019 0 0.5
Mycobacterium leprae PROBABLE POLYPRENYL-DIPHOSPHATE SYNTHASE GRCC1 (POLYPRENYL PYROPHOSPHATE SYNTHETASE) 0.019 0 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 1.7 nM Inhibitory concentration of total specific binding of [125I]- -PYY to HEK 293 cells transfected with Human NPY-Y5 cDNA (compound prepared by manual synthesis technique) ChEMBL. 11934581
IC50 (binding) = 1.7 nM Inhibitory concentration of total specific binding of [125I]- -PYY to HEK 293 cells transfected with Human NPY-Y5 cDNA (compound prepared by manual synthesis technique) ChEMBL. 11934581
IC50 (binding) = 2.9 nM Inhibitory concentration of total specific binding of [125I]- -PYY to HEK 293 cells transfected with the Human NPY-Y5 cDNA (compound prepared by parallel synthesis technique) ChEMBL. 11934581
IC50 (binding) = 2.9 nM Inhibitory concentration of total specific binding of [125I]- -PYY to HEK 293 cells transfected with the Human NPY-Y5 cDNA (compound prepared by parallel synthesis technique) ChEMBL. 11934581
Inhibition (binding) = 28.7 % Tested for the inhibition of [125I]-PYY binding to HEK 293 cells stably expressed with human neuropeptide NPY Y5 receptor at a concentration of 10e-9 M ChEMBL. 11934581
Inhibition (binding) = 28.7 % Tested for the inhibition of [125I]-PYY binding to HEK 293 cells stably expressed with human neuropeptide NPY Y5 receptor at a concentration of 10e-9 M ChEMBL. 11934581
Inhibition (binding) = 74.6 % Tested for the inhibition of [125I]-PYY binding to HEK 293 cells stably expressed with human neuropeptide NPY Y5 receptor at a concentration of 10e-8 M ChEMBL. 11934581
Inhibition (binding) = 74.6 % Tested for the inhibition of [125I]-PYY binding to HEK 293 cells stably expressed with human neuropeptide NPY Y5 receptor at a concentration of 10e-8 M ChEMBL. 11934581
Inhibition (binding) = 84.7 % Tested for the inhibition of [125I]-PYY binding to HEK 293 cells stably expressed with human neuropeptide NPY Y5 receptor at a concentration of 10e-6 M ChEMBL. 11934581
Inhibition (binding) = 84.7 % Tested for the inhibition of [125I]-PYY binding to HEK 293 cells stably expressed with human neuropeptide NPY Y5 receptor at a concentration of 10e-6 M ChEMBL. 11934581
Inhibition (binding) = 101.3 % Tested for the inhibition of [125I]-PYY binding to HEK 293 cells stably expressed with human neuropeptide NPY Y5 receptor at a concentration of 10e-7 M ChEMBL. 11934581
Inhibition (binding) = 101.3 % Tested for the inhibition of [125I]-PYY binding to HEK 293 cells stably expressed with human neuropeptide NPY Y5 receptor at a concentration of 10e-7 M ChEMBL. 11934581

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.